Ischemia Reperfusion Injury Therapeutics Market - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

Ischemia reperfusion injury (IRI), also known as reoxygenation injury, is tissue damage that arises when blood supply returns to the tissue (reperfusion) after a period of lack of oxygen (ischemia). The symptoms of ischemia injury include bradycardia, headache, hypertension, and seizures.

Market Dynamics

The increase in the number of tissue damage cases and the growing awareness about treatment of reperfusion injury are major factors boosting growth of the global ischemia reperfusion therapeutics market. Moreover, introduction of novel drugs for treatment of complications related to ischemia reperfusion, and the rising research & development activities are propelling the market growth. For instance, in November 2019, Faraday Pharmaceuticals announced positive top-line results from the phase II trial of FDY-5301 for ischemia reperfusion injury therapeutics treatment.

Moreover, factors such as the rising incidence of ischemic reperfusion injury across the globe, and strategic acquisitions of key players for developing novel treatment are expected to favor growth of the market during the period of forecast.

Key features of the study:

• This report provides in-depth analysis of the global ischemia reperfusion injury therapeutics market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• The study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
• It profiles key players in the global ischemia reperfusion injury therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
• Key players covered as a part of this study are Omeros Corporation, Nyken B.V., Opsona Therapeutics Limited, Pharming Group N.V., Orexo AB, PledPharma AB, Proteo, Inc., Prolong Pharmaceuticals, Prothix BV, Zealand Pharma A/S, Stealth BioTherapeutics Inc., Amyndas Pharmaceuticals LLC, Antipodean Pharmaceuticals, Inc., Angion Biomedica Corp., Bayer AG, Bolder Biotechnology, Inc., Biomedica Management Corporation, Curatis Pharma GmbH, Erimos Pharmaceuticals, LLC, Ensemble Therapeutics Corporation, and Gilead Sciences, Inc.
• Insights from this report would allow marketers and management authorities of companies to make an informed decision with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• The global ischemia reperfusion injury therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers in the global ischemia reperfusion therapeutics market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

Global Ischemia Reperfusion Injury Therapeutics Market, By Indication:

• Heart Injury
• Kidney Injury
• Intestine Injury
• Other Injury

Global Ischemia Reperfusion Injury Therapeutics Market, By Distribution Channel:

• Retail Pharmacies
• Hospital Pharmacies
• Others

Global Ischemia Reperfusion Injury Therapeutics Market, By Region:

• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Country/Region
• South Africa
• Central Africa
• North Africa

Company Profiles

• Omeros Corporation
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Highlights
• Strategies
• Nyken B.V.
• Opsona Therapeutics Limited
• Pharming Group N.V.
• Orexo AB
• PledPharma AB
• Proteo, Inc.
• Prolong Pharmaceuticals
• Prothix BV
• Zealand Pharma A/S
• Stealth BioTherapeutics Inc.
• Amyndas Pharmaceuticals LLC
• Antipodean Pharmaceuticals, Inc.
• Angion Biomedica Corp.
• Bayer AG
• Bolder Biotechnology, Inc.
• Biomedica Management Corporation
• Curatis Pharma GmbH
• Erimos Pharmaceuticals, LLC
• Ensemble Therapeutics Corporation
• Gilead Sciences, Inc.

“*” marked represents similar segmentation in other categories in the respective section.